Ongoing Clinical Trials
Validate the Nanostring nCounter Gene Expression Assay which has shown to be a highly reproducible method for detecting the expression of up to 770 genes in a single reaction with high sensitivity. We will use allograft biopsy tissues from a biorepository of an established patient cohorts with antibody mediated rejection, t-cell mediated rejection, BK virus, and normal.
PI: Neetika Garg, MD
Hope Meets Gratitude
Determine whether renal B cell inflammatory mediators predict allograft failure in kidney transplant patients with prevalent TG. We will use allograft biopsy tissues from a biorepository of an established patient cohort with TG to determine the association of tissue BAFF and APRIL with allograft failure.
PI: Sarah Panzer, MD
Phase 2 Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
PPD & Alnylam Pharm
PI: Ali Gardezi, MD
Serologic and Urinary Predictors of Outcomes in Renal Transplant (SUPORT)
Identify serologic and urinary analytes that predict patient and graft outcomes following renal transplantation. Outcomes of interest include mortality, graft failure, acute rejection events, and changes in graft function.
Urine Biorepository - Hope Meets Gratitude
The goal is to create a ROC curve to predict delayed graft function in kidney transplant recipients by using urine biomarker assay. The primary objective is to determine the range of variation in the urine biomarker assay. The primary objective is to determine the range of variation in the urine biomarker [TIMP-2] X [IGFB7] assay in living donor and deceased donor kidney transplant recipients in the first week after transplant to predict delayed graft function (DGF) after kidney transplant.
PI: Tripti Singh, MD